Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy-Reference-Cited by-同舟云学术

Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy

Published:2023-04-26 Issue:8 Volume:72 Page:2717-2728
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Inoue Yusuke,Inui Naoki,Karayama Masato,Asada Kazuhiro,Fujii Masato,Matsuura Shun,Uto Tomohiro,Hashimoto Dai,Matsui Takashi,Ikeda Masaki,Yasui Hideki,Hozumi Hironao,Suzuki Yuzo,Furuhashi Kazuki,Enomoto Noriyuki,Fujisawa Tomoyuki,Suda Takafumi

Funder

Chugai Pharmaceutical

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03453-z.pdf

Reference46 articles.

1. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

2. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

3. Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl J Med 375:1823–1833